Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
7.8
Journals
Vaccines
Special Issues
Public Health: Infectious Diseases and Vaccines
share announcement

Public Health: Infectious Diseases and Vaccines

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Vaccines and Public Health".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 1694

Special Issue Editor

Prof. Dr. Sultan Ayoub Meo

E-Mail Website
Guest Editor
College of Medicine, Riyadh, Saudi Arabia
Interests: vaccine

Special Issue Information

Dear Colleagues,

Infectious diseases have been a major public health concern throughout human history, causing regional outbreaks and global pandemics, and have reshaped societies. Infectious diseases often result from interactions among humans, animals, and the environment. Globalization has made infectious diseases a global concern, requiring international cooperation in surveillance, research, and response.

The One Health approach recognizes the interconnectedness of these factors and emphasizes interdisciplinary collaboration. Despite the great advancements achieved in medical sciences, infectious diseases continue to pose significant challenges to public health worldwide. Their impact on global morbidity and mortality underscores the urgency of developing and implementing effective prevention, surveillance, and control strategies. Infectious disease outbreaks demand a rapid and coordinated response to prevent further spread and mitigate their impact. Public health strategies are paramount in mitigating the burden of infectious diseases. Vaccination is one of the most effective public health interventions against infectious diseases.

I would like to invite the global science community to submit articles to this Special Issue. We will provide you with a fast peer-review process to ensure the timely publication of your articles.

Prof. Dr. Sultan Ayoub Meo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1601 KiB  
Article
Baseline Pneumococcal IgG Levels and Response to 23-Valent Pneumococcal Polysaccharide Vaccine among Adults from Beijing, China
by Shanshan Zhou, Min Lv, Shuang Bai, Weixin Chen, Wei Zhao, Jian Wang, Ao Zhang, Jing Li, Hui Xie, Yanqing Gao, Dongmei Li and Jiang Wu
Vaccines 2023, 11(12), 1780; https://doi.org/10.3390/vaccines11121780 - 29 Nov 2023
Cited by 1 | Viewed by 1420
Abstract
Purpose: To investigate the baseline levels of serotype-specific IgG antibodies to Streptococcus pneumoniae (S. pneumoniae) and assess their impact on the assessment of vaccine immunogenicity. Methods: We used a subset of serum samples from a randomized controlled trial. The blood of 584 healthy [...] Read more.
Purpose: To investigate the baseline levels of serotype-specific IgG antibodies to Streptococcus pneumoniae (S. pneumoniae) and assess their impact on the assessment of vaccine immunogenicity. Methods: We used a subset of serum samples from a randomized controlled trial. The blood of 584 healthy participants was collected on day 0 before and day 28 after the 23-valent pneumococcal polysaccharide vaccine (PPSV23) vaccination. Serotype-specific IgG against PPSV23-covered serotypes were measured by the World Health Organization (WHO) reference enzyme-linked immunosorbent assay (ELISA). Vaccine immunogenicity was compared using conversion rates (proportion of participants with IgG levels following immunization that are 2-fold greater than the baseline) and geometric mean fold rises (GMFRs) between the two groups, which were grouped according to pre-vaccination (baseline) IgG antibody levels. Results: Our data showed that over half of individuals have baseline IgG levels for 15 out of 23 serotypes above 1.3 µg/mL, and geometric mean concentrations (GMCs) were generally higher in the elderly group and the female group; significant differences were found in 15 serotypes for vaccine immunogenicity based on the seroconversion rate or GMFRs between individuals with baseline IgG ≥ 1.3 µg/mL and individuals with baseline IgG < 1.3 µg/mL. The seroconversion rate decreased with the increase of baseline IgG levels according to a linear regression model. Conclusions: The assessment of vaccine immunogenicity could be impacted by the fact that many adults had high baseline antibody levels. This study is registered in the Chinese Clinical Trial Registry, number NCT05298800. Full article
(This article belongs to the Special Issue Public Health: Infectious Diseases and Vaccines)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop